Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 0.37 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 4/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2359800 | 0.82 | NPY5R (0.37) | NPY5RDEGS1USP30 | |
| SCHEMBL13362203 | 0.82 | NPY5R (0.37) | NPY5RDEGS1USP30 | |
| SCHEMBL2315190 | 0.80 | NPY5R (0.60) | NPY5RDEGS1USP30 | |
| SCHEMBL2317422 | 0.80 | NPY5R (0.49) | NPY5RDEGS1USP30 | |
| SCHEMBL2318725 | 0.80 | NPY5R (0.60) | NPY5RDEGS1USP30 | |
| SCHEMBL2315496 | 0.80 | NPY5R (0.49) | NPY5RDEGS1USP30 | |
| SCHEMBL2422098 | 0.79 | NPY5R (0.47) | NPY5RDEGS1 | |
| SCHEMBL2416950 | 0.77 | NPY5R (0.43) | NPY5RDEGS1 | |
| SCHEMBL2359498 | 0.76 | DEGS1 (0.43) | NPY5RDEGS1 | |
| SCHEMBL2315476 | 0.74 | NPY5R (0.42) | NPY5RDEGS1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | NPY5R 1/4885DEGS1 3961/4885IDH1 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.